Advanced search
Publication Cover
Hematology Volume 21, 2016 - Issue 9
Submit an article Journal homepage
1,361
Views
12
CrossRef citations to date
0
Altmetric
HEMATOLOGICAL MALIGNANCY

Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas

Bo JiaDepartment of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing100021, China
,
Shaoxuan HuDepartment of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing100021, China
,
Jianliang YangDepartment of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing100021, China
,
Shengyu ZhouDepartment of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing100021, China
,
Peng LiuDepartment of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing100021, China
,
Yan QinDepartment of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing100021, China
,
Lin GuiDepartment of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing100021, China
,
Sheng YangDepartment of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing100021, China
,
Hua LinDepartment of Medical Record Library, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing100021, China
,
Changgong ZhangDepartment of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing100021, China
,
Puyuan XingDepartment of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing100021, China
,
Lin WangDepartment of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing100021, China
,
Mei DongDepartment of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing100021, China
,
Liqiang ZhouDepartment of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing100021, China
,
Yan SunDepartment of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing100021, China
,
Xiaohui HeDepartment of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing100021, ChinaCorrespondence[email protected]
&
Yuankai ShiDepartment of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing100021, ChinaCorrespondence[email protected]
[email protected]
 show all
Pages 536-541 | Published online: 06 Apr 2016

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Zhao Jennifer C, Jaszczur Sara Mohamed, Afifi Salma & Foss Francine. (2020) Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Expert Review of Hematology 13:6, pages 577-583.
Read now
Shu Deng, Shenyun Lin, Jianping Shen & Yuqing Zeng. (2019) Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis. OncoTargets and Therapy 12, pages 2335-2342.
Read now
Tony Reiman, Kerry J. Savage, Michael Crump, Matthew C. Cheung, David MacDonald, Rena Buckstein, Stephen Couban, Eugenia Piliotis, Kevin Imrie, David Spaner, Sudeep Shivakumar, John Kuruvilla, Diego Villa, Lois E. Shepherd, Tanya Skamene, Chad Winch, Bingshu E. Chen & Annette E. Hay. (2019) A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†. Leukemia & Lymphoma 60:4, pages 912-919.
Read now

Articles from other publishers (9)

Haizhu Chen, Yunxia Tao, Yu Zhou, Peng Liu, Jianliang Yang, Xiaohui He, Shengyu Zhou, Yan Qin, Yongwen Song, Lin Gui, Changgong Zhang, Sheng Yang & Yuankai Shi. (2022) The clinical features, treatment, and prognostic factors for peripheral T‐cell lymphomas: A single‐institution analysis of 240 Chinese patients. Asia-Pacific Journal of Clinical Oncology.
Crossref
Ajibade O Ashaye, Heather Burnett, Seye Abogunrin, Hemangi Panchmatia, Olga Ovcinnikova & Mehul Dalal. (2022) The clinical and economic burden of peripheral T-cell lymphoma: a systematic literature review. Future Oncology 18:4, pages 519-535.
Crossref
Yang Zhu, Shu Tian, Lan Xu, Yujie Ma, Wenhao Zhang, Lifeng Wang, Lina Jin, Chuanxu Liu, Chuanying Zhu, Zhichao Li, Siguo Hao, Hua Zhong, Hao Ding & Rong Tao. (2021) GELAD chemotherapy with sandwiched radiotherapy for patients with newly diagnosed stage IE/IIE natural killer/T‐cell lymphoma: a prospective multicentre study. British Journal of Haematology 196:4, pages 939-946.
Crossref
Yingjie Qing, Hui Li, Yunzi Zhao, Po Hu, Xiangyuan Wang, Xiaoxuan Yu, Mengyuan Zhu, Hongzheng Wang, Zhanyu Wang, Qinglong Guo & Hui Hui. (2021) One-Two Punch Therapy for the Treatment of T-Cell Malignancies Involving p53-Dependent Cellular Senescence. Oxidative Medicine and Cellular Longevity 2021, pages 1-20.
Crossref
Ming-Ci Cai, Shu Cheng, Xin Wang, Jian-Da Hu, Yong-Ping Song, Yao-Hui Huang, Zi-Xun Yan, Yu-Jie Jiang, Xiao-Sheng Fang, Xiao-Yun Zheng, Li-Hua Dong, Meng-Meng Ji, Li Wang, Peng-Peng Xu & Wei-Li Zhao. (2020) CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial. Genome Medicine 12:1.
Crossref
Pamela B. Allen & Barbara Pro. (2020) Therapy of Peripheral T Cell Lymphoma: Focus on Nodal Subtypes. Current Oncology Reports 22:5.
Crossref
Xuyan Liu, Mingzi Yang, Meng Wu, Wen Zheng, Yan Xie, Jun Zhu, Yuqin Song & Weiping Liu. (2018) A retrospective study of the CHOP, CHOPE, and CHOPE/G regimens as the first-line treatment of peripheral T-cell lymphomas. Cancer Chemotherapy and Pharmacology 83:3, pages 443-449.
Crossref
Mary Gleeson, Clare Peckitt, Ye Mong To, Laurice Edwards, Jacqueline Oates, Andrew Wotherspoon, Ayoma D Attygalle, Imene Zerizer, Bhupinder Sharma, Sue Chua, Ruwaida Begum, Ian Chau, Peter Johnson, Kirit M Ardeshna, Eliza A Hawkes, Marian P Macheta, Graham P Collins, John Radford, Adam Forbes, Alistair Hart, Silvia Montoto, Pamela McKay, Kim Benstead, Nicholas Morley, Nagesh Kalakonda, Yasmin Hasan, Deborah Turner & David Cunningham. (2018) CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. The Lancet Haematology 5:5, pages e190-e200.
Crossref
Yuankai Shi, Bo Jia, Wei Xu, Wenyu Li, Ting Liu, Peng Liu, Weili Zhao, Huilai Zhang, Xiuhua Sun, Haiyan Yang, Xi Zhang, Jie Jin, Zhengming Jin, Zhiming Li, Lugui Qiu, Mei Dong, Xiaobing Huang, Yi Luo, Xiaodong Wang, Xin Wang, Jianqiu Wu, Jingyan Xu, Pingyong Yi, Jianfeng Zhou, Hongming He, Lin Liu, Jianzhen Shen, Xiaoqiong Tang, Jinghua Wang, Jianmin Yang, Qingshu Zeng, Zhihui Zhang, Zhen Cai, Xiequn Chen, Kaiyang Ding, Ming Hou, Huiqiang Huang, Xiaoling Li, Rong Liang, Qifa Liu, Yuqin Song, Hang Su, Yuhuan Gao, Lihong Liu, Jianmin Luo, Liping Su, Zimin Sun, Huo Tan, Huaqing Wang, Jingwen Wang, Shuye Wang, Hongyu Zhang, Xiaohong Zhang, Daobin Zhou, Ou Bai, Gang Wu, Liling Zhang & Yizhuo Zhang. (2017) Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. Journal of Hematology & Oncology 10:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.